Over the past three decades, American healthcare has undergone one of the most dramatic consolidations in modern economic history. Hospital systems have absorbed independent facilities, physician practices have been swallowed by larger networks, and insurers have merged into a handful of dominant players.

The evidence on consequences is increasingly clear. Studies repeatedly show that hospital mergers raise prices, often without improving quality. Physician practice consolidation increases costs to patients and payers. Vertical integration between insurers and providers complicates competition in ways regulators struggle to anticipate.

Yet anti-trust enforcement has remained remarkably permissive. The Federal Trade Commission and Department of Justice review hundreds of healthcare transactions annually, but block only a handful. Understanding why requires examining not just the will to enforce, but the structural limitations that have made aggressive enforcement difficult—even when regulators have wanted to act.

At the heart of anti-trust analysis lies a deceptively simple question: what is the relevant market? In healthcare, this question has proven extraordinarily difficult to answer, and how regulators have answered it has frequently determined whether mergers proceed.

Traditionally, agencies defined hospital markets broadly, often encompassing wide geographic regions and treating different service lines as substitutes. A merging hospital could argue that patients had options across an entire metropolitan area, or that an academic medical center competed with community hospitals for routine care. These broad definitions made market concentration appear lower than patients actually experienced.

The reality is that healthcare markets are often hyperlocal and service-specific. A patient needing emergency cardiac care cannot meaningfully choose between hospitals fifty miles apart. A pregnant woman selecting an obstetrician operates within a narrow geographic radius. Yet for years, courts accepted broader definitions, partly because the economic tools to define markets more precisely were still developing.

Recent enforcement actions have begun applying narrower, more realistic market definitions—but the legacy of permissive analysis persists. Many of the consolidations now driving prices upward were approved under definitional frameworks that economists now recognize as flawed. Unwinding consolidation is far harder than preventing it.

Takeaway

How you draw the boundaries determines what you see. In healthcare, the wrong map made monopolies look like competition.

Healthcare mergers come wrapped in compelling narratives. Combined entities promise better care coordination, shared electronic records, standardized clinical protocols, and the financial stability needed to invest in quality improvement. These efficiency claims have historically carried significant weight with regulators.

The problem is that the evidence supporting these promises has been consistently weak. Post-merger studies rarely show the predicted quality gains. Care coordination across newly combined systems often deteriorates before it improves. Promised investments materialize unevenly, and the cost savings frequently fail to reach patients.

Why have unsubstantiated claims carried such weight? Part of the answer lies in healthcare's special status. Regulators have been reluctant to block mergers that hospitals frame as essential to clinical mission, particularly when academic centers or safety-net facilities are involved. The fear of impeding genuine clinical improvement has tilted analysis toward accepting efficiency arguments at face value.

More recent research has begun forcing a recalibration. Economists studying completed mergers find that the predicted benefits rarely appear, while price increases are nearly universal. Regulators are increasingly skeptical of efficiency claims absent rigorous evidence—but only after decades of approvals built on assumptions that have not held up.

Takeaway

A promise about the future is not the same as evidence from the past. When the stakes are health and cost, the burden of proof should match.

Even with better analytical frameworks, enforcement faces a brute mathematical problem. The FTC and DOJ Antitrust Division together employ a relatively small number of healthcare-focused attorneys and economists. They face a deal flow numbering in the hundreds annually, with each transaction requiring economic modeling, market analysis, and often litigation against well-resourced opposing counsel.

Healthcare mergers are particularly resource-intensive to challenge. They require expert witnesses, detailed claims data analysis, and sophisticated econometric work. A single contested hospital merger can consume staff time equivalent to dozens of routine reviews. Agencies must therefore triage aggressively, focusing on the most egregious cases and letting marginal ones proceed unchallenged.

The asymmetry of resources matters enormously. A health system pursuing acquisition can deploy nearly unlimited legal and economic firepower. Federal agencies, operating under fixed budgets that have grown slowly relative to the volume and complexity of transactions, simply cannot match this firepower at scale. State attorneys general, who have authority to act, face even tighter constraints.

This structural mismatch produces a predictable pattern: aggressive enforcement against a small number of clear-cut cases, tacit acceptance of borderline transactions, and a market that learns over time which deals will draw scrutiny and which will not. Consolidation strategies have evolved to fly under the threshold of meaningful review.

Takeaway

Enforcement is not just about laws and intentions—it is about capacity. When watchdogs are outnumbered and outspent, the rules on paper bend in practice.

Healthcare consolidation did not happen because regulators were absent. It happened because the tools, frameworks, and resources available to regulators were inadequate to the scale and sophistication of the activity they were meant to police.

The lessons extend beyond healthcare. Anti-trust enforcement depends on getting market definitions right, demanding evidence rather than accepting promises, and matching enforcement capacity to the complexity of regulated industries. Failure on any of these dimensions creates space for concentration that, once established, is enormously difficult to reverse.

What remains an open question is whether the recent shift toward more rigorous analysis can do more than slow further consolidation. The structure of American healthcare has already been reshaped. Future policy may need to look beyond merger review toward more active interventions in markets that are no longer competitive in any meaningful sense.